OLDMicrodosing
Microdosing, the practice of consuming sub-perceptual doses of psychedelics, is garnering attention for its potential in enhancing mental health and cognitive function. Emerging research suggests that compounds like psilocybin and LSD may offer therapeutic benefits in various psychiatric conditions when administered in microdoses.
What is OLDMicrodosing?
Microdosing involves the administration of a small fraction of a standard recreational dose of a psychedelic substance, typically resulting in minimal or no psychoactive effects but potentially providing therapeutic benefits.
The primary symptoms targeted through microdosing include anxiety, depression, and cognitive deficits, which may arise from various conditions such as major depressive disorder and generalized anxiety disorder.
There is a growing interest in the neuropharmacology of psychedelics; compounds like psilocybin and LSD primarily influence serotonin receptors, particularly the 5-HT2A receptor, which is linked to mood regulation and cognitive function.
Current Treatments
Standard treatments for conditions addressed by microdosing typically include SSRIs, therapy, and other medications aimed at mood stabilization and cognitive enhancement.
Psychedelic Effect Matrix
Systematic comparison of compound efficacy and evidence levels for OLDMicrodosing.
| Compound | Magnitude | Evidence | Consistency |
|---|---|---|---|
| Psilocybin Research indicates that psilocybin microdosing can improve mood and cognitive functioning in controlled settings. | Medium | Moderate | Consistent |
| LSD LSD microdosing has been shown to enhance creativity and reduce anxiety, supported by ongoing studies. | Medium | Moderate | Consistent |
| MDMA MDMA's effects at microdoses are less researched compared to psilocybin and LSD, leading to less definitive findings. | Small | Low | Inconsistent |
Psilocybin and OLDMicrodosing
When used in microdoses, psilocybin may enhance connectivity in the brain and promote neuroplasticity, leading to improved mood and cognitive flexibility. Patients report increased emotional openness and reductions in anxiety, underpinning its potential as a complementary therapeutic option in treating mental health disorders.
LSD and OLDMicrodosing
LSD microdosing has been associated with enhanced creative thinking and problem-solving abilities without the full psychedelic experience. Users often report heightened awareness and improved emotional regulation, suggesting its utility in acute anxiety management and long-term mood improvement.
Key Insights
- 1
Studies indicate that microdosing can lead to significant improvements in mood and creativity without substantial side effects, unlike traditional antidepressants.
- 2
Psilocybin microdosing is emerging as a possible alternative to SSRIs, aiming to treat depression and anxiety effectively.
- 3
Recent research has shown that the psychological effects of acute psychedelic experiences can serve as predictors of therapeutic outcomes.
- 4
The market for psychedelics is expanding, with increased legislative support and public interest driving more rigorous clinical trials on microdosing.
Industrial Landscape
Key players in the psychedelic research and therapy space include organisations such as MAPS (Multidisciplinary Association for Psychedelic Studies) and various biotech firms focusing on psychedelic compounds.
Quick Indicators
\"Ongoing clinical evaluations are investigating OLDMicrodosing as a primary indication for various psychedelic compounds.\"
Key Organizations
4 ConnectedDelix Therapeutics
Delix Therapeutics is harnessing the power of neuroplastogens, a novel class of compounds designed to bring about a new paradigm in brain health therapeutics with treatments intended to be safe, fast-acting, and long-lasting. Through its discovery platform, Delix has identified non-hallucinogenic versions of psychedelic compounds with favorable safety and therapeutic profiles. The company was co-founded in 2019 by David E. Olson and Nick Haft, building upon Olson's discovery at the University of California, Davis, of several novel psychoplastogens that have significant therapeutic potential in preclinical models, without hallucinogenic side effects. Delix's treatments are designed to address the root cause of neuropsychiatric conditions by repairing the underlying synaptic damage through targeted neuroplasticity. To date, the company has synthesized over 2000 novel psychoplastogens, many of which are analogs of known psychedelics such as ibogaine and 5-MeO-DMT. Their lead compound, zalsupindole (DLX-001), produces the same rapid and sustained structural and functional plasticity as ketamine, psilocybin, and DMT, without inducing hallucinations or dissociation. Recent Phase I data have demonstrated that DLX-001 is associated with robust signs of CNS engagement and a favorable safety and tolerability profile, with no serious adverse events reported to date. The company's compounds are tailored for swift neuronal repair and can be taken at-home, providing significant advantages to patients, their loved ones, and healthcare providers. Delix focuses on developing non-hallucinogenic psychoplastogens as scalable alternatives to first-generation hallucinogenic psychoplastogens like ketamine and psilocybin.
MAPS
The description of the stakeholder
Lykos Therapeutics
Longer description of Lykos .. lorem ipsum ..
Leiden University
Leiden University doesn't have a dedicated research centre for psychedelics. However, several staff members from their medical centre and psychology faculty are working with psychedelics. Researchers here are working with other universities including Utrecht University as well as Compass Pathways.
Prominent Researchers
1 LinkedConnected Evidence
The latest clinical data points and verified academic findings associated with OLDMicrodosing.